A Phase II Study of Gemcitabine and Cisplatin in Unresectable Malignant Mesothelioma

Pts must have histologically confirmed unresectable malignant mesothelioma of the pleura; histologically confirmed dx of epithelial, fibrosarcomatous or mixed type of mesothelioma; bidimensionally measurable disease documented w/in 28 days prior to registration; all evaluable and non-evaluable disease assessed w/in 42 days prior to reg; no CNS mets; no prior chemo or radiotherapy for any reason; prior surgery okay if at least 4 weeks have elapsed and pt has recovered from all side effects; PS 0-2; WBC >= 3,000; PLT >/= ILLN; Bilirubin <= 2mg/dl; SGOT or SGPT <= 2.5 x IULN; Creatinine <= 2 x IULN; Creatinine Clearance >/= 60 ml/min; chest x-ray w/in 28 days prior to reg.